Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A, Kaneko S, Endo S, Minowa Y, Ayukawa H, Hirano R, Nagashima F, Naruge D, Okano N, Kobayashi T, Kawai K, Furuse J, Furuta T, Shibasaki H. Yokokawa A, et al. Among authors: nagashima f. Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):317-324. doi: 10.1007/s13318-021-00675-3. Epub 2021 Feb 23. Eur J Drug Metab Pharmacokinet. 2021. PMID: 33619631
Novel single nucleotide polymorphism of UGT1A7 gene in Japanese.
Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Kodama K, Araki K, Miya T, Narabayashi M, Sasaki Y. Fujita K, et al. Among authors: nagashima f. Drug Metab Pharmacokinet. 2006 Feb;21(1):75-8. doi: 10.2133/dmpk.21.75. Drug Metab Pharmacokinet. 2006. PMID: 16547397 Free article.
Novel single nucleotide polymorphism of UGT1A9 gene in Japanese.
Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Kodama K, Araki K, Miya T, Narabayashi M, Sasaki Y. Fujita K, et al. Among authors: nagashima f. Drug Metab Pharmacokinet. 2006 Feb;21(1):79-81. doi: 10.2133/dmpk.21.79. Drug Metab Pharmacokinet. 2006. PMID: 16547398 Free article.
[Systemic chemotherapy for cholangiocarcinoma].
Furuse J, Suzuki E, Hirokawa S, Kitamura H, Nagashima F. Furuse J, et al. Among authors: nagashima f. Nihon Shokakibyo Gakkai Zasshi. 2010 Jul;107(7):1102-8. Nihon Shokakibyo Gakkai Zasshi. 2010. PMID: 20616478 Review. Japanese. No abstract available.
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y. Fujita K, et al. Among authors: nagashima f. Drug Metab Dispos. 2011 Feb;39(2):161-4. doi: 10.1124/dmd.110.035451. Epub 2010 Oct 27. Drug Metab Dispos. 2011. PMID: 20980446 Clinical Trial.
[Managements for jaundice].
Furuse J, Toki M, Kitamura H, Hirokawa S, Nagashima F. Furuse J, et al. Among authors: nagashima f. Gan To Kagaku Ryoho. 2011 Apr;38(4):540-4. Gan To Kagaku Ryoho. 2011. PMID: 21498981 Japanese.
Inhibitor of MEK1/2, selumetinib, for biliary tract cancer.
Furuse J, Nagashima F. Furuse J, et al. Among authors: nagashima f. Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):579-81. doi: 10.1586/egh.11.58. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21910575
Role of chemotherapy in treatments for biliary tract cancer.
Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F. Furuse J, et al. Among authors: nagashima f. J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):337-41. doi: 10.1007/s00534-011-0494-2. J Hepatobiliary Pancreat Sci. 2012. PMID: 22456744 Review.
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: nagashima f. Oncology. 2012;82(4):242-8. doi: 10.1159/000337225. Epub 2012 Apr 12. Oncology. 2012. PMID: 22508373 Clinical Trial.
213 results